
Professor Iain Chapple
Professor of Periodontology and Consultant in Restorative Dentistry
Principal Investigator & Group Lead
The Periodontal Research Group (PRG) investigates fundamental mechanisms of how gum diseases develop and their links to general health and diseases like diabetes, kidney disease, rheumatoid arthritis and other diseases of ageing. Using knowledge from their discovery science, the PRG translate their work into new diagnostic and therapeutic approaches.

Professor of Periodontology and Consultant in Restorative Dentistry
Principal Investigator & Group Lead

Associate Professor
Principal Investigator & Group Lead
Principal Investigator
Principal Investigator
Principal Investigator
Principal Investigator
View profile
Principal Investigator
Principal Investigator
Principal Investigator & Doctoral Fellow
The periodontal research group (PRG) focus on unravelling the complex pathobiological pathways that govern periodontal inflammation at the molecular, cellular and clinical levels. Identifying mechanisms underpinning disease pathogenesis and the inter-relationships between periodontal inflammation and other chronic inflammatory diseases (such as rheumatoid arthritis and chronic kidney disease) and the ageing immune system are key goals. We have a particular interest in neutrophil biology and host-microbial interactions.
We are increasingly adopting a stratified medicine approach to common disease pathways that may explain periodontal-systemic links through our expertise in analytical epidemiology. We work with large cohorts and datasets, employing bioinformatics approaches to understand the complex bio-clinical datasets we create.
Our work includes a multi-omics approach in the area of periodontal infection and immunity and we have expertise in proteomics, lipidomics, transcriptomics and the oral microbiome. These fundamental approaches allow us to work with rare diseases like Epidermolysis Bullosa, Papillon-Lefevre Syndrome and Myelomatosis.
Translation into improved care is a priority and achieved through clinical trials to provide novel diagnostics and host-modulating therapies. Indeed, we have spun out 2 companies in the risk and diagnostics arena, and filed 10 patents (2019-2020) in the saliva diagnostics space.
Bardhan A, Bruckner-Tuderman L, Chapple ILC et al. 2020. Epidermolysis bullosa. Nature Reviews, Disease Primers. 6:78. https://doi.org/10.1038/s41572-020-0210-0
Ademowoa OS, Sharma P, Cockwell P, Reis A, Chapple ILC, Griffiths HR, Dias IHK. Distribution of plasma oxidised phosphocholines in chronic kidney disease and periodontitis as a co-morbidity. Free Radical Biol & Med. 2019, https://doi.org/10.1016/j.freeradbiomed.2019. 10.012.
Chicca IJ, Milward MR, Chapple IL, Griffiths G, Benson R, Dietrich T, Cooper PR. Development and application of high-content Biological screening for Modulators of NET Production. Frontiers in Immunol 2018, 9, 337. https://doi.org/10.3389/fimmu.2018.00337
Roberts H, White P, Dias I, McKaig S, Veeramachaneni R, Thakker N, Grant M, Chapple I. Characterisation of neutrophil function in Papillon-Lefevre Syndrome. J Leukocyte Biology. 2016, 100; 433-444. https://doi.org/10.1189/jlb.5A1015-489R
Spengler J, Lugonja B, Ytterberg AJ, Zubarev RA, Creese A, Pearson M, Grant M, Milward M, Lundberg K, Buckley C, Filer A, Raza K, Cooper P, Chapple ILC, Scheel-Toellner D. Release of active peptidyl arginine deiminases by neutrophils can explain production of extracellular citrullinated autoantigens in RA synovial fluid. Arthritis & Rheumatol 2015: 67; 3135-3145. https://doi.org/10.1002/art.39313